Diabetes is one of the most common chronic conditions in the United States, affecting more than 37 million Americans — and Miami-Dade County has some of the highest rates in Florida, particularly among the Hispanic community. Type 2 diabetes develops when the body's cells become resistant to insulin or the pancreas cannot produce enough insulin to maintain normal blood sugar levels. Left unmanaged, diabetes causes progressive damage to blood vessels and nerves throughout the body, leading to complications including heart disease, stroke, kidney failure, vision loss, and neuropathy. The most important thing to understand about diabetes is that it is highly manageable. With the right care team, personalized treatment plan, and consistent monitoring, most people with diabetes can live full, healthy, active lives. The science has never been better — GLP-1 receptor agonists, SGLT-2 inhibitors, and continuous glucose monitoring technologies have transformed what is achievable in diabetes management. At Viva Medical Center in Doral, FL, our board-certified primary care physicians provide comprehensive diabetes management for patients throughout Miami-Dade. We combine evidence-based medicine with culturally appropriate, bilingual care to help you achieve your health goals.
Types of Diabetes We Manage
Our team manages all forms of diabetes and related metabolic conditions:
- Type 2 diabetes — the most common form, driven by insulin resistance and relative insulin deficiency
- Type 1 diabetes — autoimmune destruction of pancreatic beta cells; requires insulin therapy; managed in coordination with endocrinology
- Prediabetes — A1C 5.7–6.4% or fasting glucose 100–125 mg/dL; reversible with intervention
- Gestational diabetes — diabetes developing during pregnancy; requires close monitoring
- LADA (Latent Autoimmune Diabetes in Adults) — slow-onset autoimmune diabetes often misclassified as type 2
Our Diabetes Management Approach
Effective diabetes management at Viva Medical Center is comprehensive and individualized:
- A1C monitoring every 3–6 months with target < 7% for most patients (individualized per ADA 2025 guidelines)
- Fasting and postprandial blood glucose monitoring with personalized targets
- Annual kidney function panel — eGFR and urine albumin-to-creatinine ratio (uACR)
- Annual dilated eye exam referral and podiatric foot exam
- GLP-1 receptor agonist therapy (semaglutide, tirzepatide) for eligible patients — reduces A1C 1–2%+ and promotes weight loss
- SGLT-2 inhibitor therapy for cardiovascular and renal protection when indicated
- Culturally appropriate nutritional counseling — adapted for traditional Latin American dietary patterns
- Physical activity planning — ADA recommends 150 min/week moderate aerobic activity
- Lipid and blood pressure management integrated into diabetes care
- Diabetes prevention program for prediabetes patients — 58% reduction in progression to diabetes with lifestyle intervention
Warning Signs That You May Have Diabetes
Many people have type 2 diabetes or prediabetes without knowing it. See your doctor if you experience:
- Increased thirst and frequent urination
- Unexplained fatigue and low energy
- Blurred vision
- Slow-healing wounds or sores
- Frequent infections (skin, urinary tract, gum)
- Numbness or tingling in hands or feet
- Unexplained weight loss (more common in type 1)
- Darkened skin in body folds (acanthosis nigricans — sign of insulin resistance)
Diabetes Complications We Help Prevent
Uncontrolled diabetes damages multiple organ systems. Proactive management at Viva Medical Center targets prevention of:
- Cardiovascular disease — heart attack and stroke risk is 2–4x higher in people with diabetes
- Diabetic kidney disease (nephropathy) — leading cause of kidney failure in the US
- Diabetic retinopathy — leading cause of new blindness in working-age adults
- Diabetic neuropathy — nerve damage causing pain, numbness, and foot complications
- Diabetic foot complications — infections and ulcers that can lead to amputation if unmanaged
- Hypoglycemia — low blood sugar, particularly in patients on insulin or sulfonylureas